Clofarabine incorporated into a 5-drug regimen
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoblastic Leukemia, Acute, Childhood
Conditions
Lymphoblastic Leukemia, Acute, Childhood
Trial Timeline
Oct 1, 2009 → Apr 1, 2011
NCT ID
NCT00991133About Clofarabine incorporated into a 5-drug regimen
Clofarabine incorporated into a 5-drug regimen is a phase 1 stage product being developed by Sanofi for Lymphoblastic Leukemia, Acute, Childhood. The current trial status is completed. This product is registered under clinical trial identifier NCT00991133. Target conditions include Lymphoblastic Leukemia, Acute, Childhood.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00991133 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoblastic Leukemia, Acute, Childhood